Skip to content

The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study

The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a UK Matched Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03835780
Enrollment
266890
Registered
2019-02-11
Start date
2019-02-01
Completion date
2019-12-01
Last updated
2025-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease, Deep Vein Thrombosis, Inflammatory Bowel Diseases, Psoriatic Arthritis, Pulmonary Embolism, Rheumatoid Arthritis, Ulcerative Colitis, Venous Thromboembolism, Venous Thromboses

Brief summary

Blood clots occurring in the legs and in the lungs are relatively common; they occur in around 3 in a 1000 people per year. They can cause disability and are also potentially life threatening. When a clot occurs in the legs it is called a deep vein thrombosis or DVT. When they occur in the lungs they are called a pulmonary embolism or PE. The risk for DVT and PE is higher in people with conditions which cause inflammation. The most common of these are inflammatory bowel disease (ulcerative colitis and Crohn's disease), rheumatoid arthritis, and psoriatic arthritis (a condition comprised of psoriasis and joint inflammation). What is not known is how much higher the risk of DVT and PE is in these groups compared with people without inflammatory disease, and what causes the excess risk in these people. This study aims to assess the measure the exact increase in risk for DVT and PE in people with these inflammatory conditions and to identify which risk factors are most strongly associated with the increased risk. These data should help with an understand the causes of blood clot risk in these inflammatory conditions and in identify targets for reducing risk.

Detailed description

Background Venous thromboembolism (VTE), comprising pulmonary embolism (PE) and deep vein thrombosis (DVT), are common and associated with significant morbidity and mortality. VTE risk is higher in chronic inflammatory conditions including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) compared to the general population. Evidence for differential VTE risk in other inflammatory diseases, notably psoriatic arthritis (PsA) and vasculitis, is more limited. Risk factors for VTE have been described in the general population, but there has been little interrogation of VTE risk factors for individuals with chronic inflammatory conditions and their association with subsequent VTE. Objective This study aims to describe the prevalence of VTE risk and risk factors in individuals with systemic inflammatory disorders in a contemporary real-world population, by disease type (IBD, RA, and PsA) and relative to a control population without systemic inflammatory disease. In the same cohorts a further comparison will be performed of the influence of VTE risk factors on risk of VTE events in individuals with systemic inflammatory disorders. Method A retrospective cohort study will be performed to compare VTE risk and VTE risk factors in adults with IBD, RA, and PsA and matched controls between January 1, 1998 and January 1, 2018, within the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network. In the cohorts with and without inflammatory conditions estimate will be determined for the risk of VTE overall, and for PE and DVT separately, using unadjusted Cox proportional hazards models, stratified by matched set (exposed cohort versus unexposed cohort), to provide overall hazard ratios for the association with each outcome. Models will be subsequently adjusted for sociodemographic and clinical and VTE risk factors in multivariable analysis to explore potentially important associations with VTE. The same analyses for each autoimmune condition will be repeated separately. Prespecified sensitivity analyses will be performed to explore the robustness of any potential associations.

Interventions

OTHERNo intervention

A observation of outcomes in usual practice

Sponsors

Pfizer
CollaboratorINDUSTRY
University of Surrey
CollaboratorOTHER
Momentum Data
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients (aged ≥18) contributing to RCGP RCS primary care database between January 1, 1998 and January 1, 2018, will be eligible for inclusion

Exclusion criteria

* People with IBD which cannot be classified or is not ulcerative colitis or Crohn's disease will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Risk of Venous Thromboembolism (VTE)A 20 year analysis period (1999-2018 inclusive)Number of participants with systemic inflammatory disorders developing VTE (a composite of pulmonary embolism (PE) and deep vein thrombosis (DVT)) compared to population controls.

Secondary

MeasureTime frameDescription
Risk of Pulmonary Embolism (PE)A 20 year analysis period (1999-2018 inclusive)Number of participants with systemic inflammatory disorders developing PE compared to population controls.
Risk of Deep Vein Thrombosis (DVT)A 20 year analysis period (1999-2018 inclusive)Number of participants with systemic inflammatory disorders developing DVT compared to population controls.

Countries

United Kingdom

Participant flow

Participants by arm

ArmCount
Controls
Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period No intervention: A observation of outcomes in usual practice
213,512
People With Ulcerative Colitis
All individuals with an existing or incident diagnosis of ulcerative colitis during the study period No intervention: A observation of outcomes in usual practice
14,182
People With Crohn's Disease
All individuals with an existing or incident diagnosis of Crohn's disease during the study period No intervention: A observation of outcomes in usual practice
9,489
People With Psoriatic Arthritis
All individuals with an existing or incident diagnosis of IBD during the study period No intervention: A observation of outcomes in usual practice
6,297
People With Rheumatoid Arthritis
All individuals with an existing or incident diagnosis of RA during the study period No intervention: A observation of outcomes in usual practice
23,410
Total266,890

Baseline characteristics

CharacteristicControlsPeople With Ulcerative ColitisPeople With Crohn's DiseasePeople With Psoriatic ArthritisPeople With Rheumatoid ArthritisTotal
Age, Continuous51.7 years
STANDARD_DEVIATION 17.8
47.2 years
STANDARD_DEVIATION 17
41.8 years
STANDARD_DEVIATION 16.6
49.2 years
STANDARD_DEVIATION 13.8
59.0 years
STANDARD_DEVIATION 15.5
49.8 years
STANDARD_DEVIATION 6.3
Alcohol intake
Alcoholism
3438 Participants217 Participants138 Participants128 Participants340 Participants4261 Participants
Alcohol intake
Alcohol level not recorded
25416 Participants1784 Participants1408 Participants559 Participants1735 Participants30902 Participants
Alcohol intake
Non-drinker
36623 Participants2371 Participants1798 Participants1035 Participants5404 Participants47231 Participants
Alcohol intake
Over recommended limits
30096 Participants2083 Participants1228 Participants1067 Participants2767 Participants37241 Participants
Alcohol intake
Within limits
117939 Participants7727 Participants4917 Participants3508 Participants13164 Participants147255 Participants
Body mass index
BMI not recorded
23754 Participants1374 Participants896 Participants459 Participants1523 Participants28006 Participants
Body mass index
Normal weight (BMI 18.5-25)
73675 Participants5721 Participants4225 Participants1576 Participants7758 Participants92955 Participants
Body mass index
Obese (BMI ≥30)
44303 Participants2367 Participants1386 Participants2071 Participants5787 Participants55914 Participants
Body mass index
Overweight (BMI 25-30)
67076 Participants4352 Participants2446 Participants2131 Participants7735 Participants83740 Participants
Body mass index
Underweight (BMI ≤18.5)
4704 Participants368 Participants536 Participants60 Participants607 Participants6275 Participants
Index of multiple deprivation (IMD) quintile
1 (most deprived)
29144 Participants1689 Participants1324 Participants803 Participants3477 Participants36437 Participants
Index of multiple deprivation (IMD) quintile
2
32323 Participants2109 Participants1518 Participants919 Participants3728 Participants40597 Participants
Index of multiple deprivation (IMD) quintile
3
41379 Participants2680 Participants1901 Participants1250 Participants4739 Participants51949 Participants
Index of multiple deprivation (IMD) quintile
4
50087 Participants3475 Participants2186 Participants1452 Participants5326 Participants62526 Participants
Index of multiple deprivation (IMD) quintile
5 (least deprived)
56209 Participants3963 Participants2350 Participants1720 Participants5651 Participants69893 Participants
Index of multiple deprivation (IMD) quintile
IMD not recorded
4370 Participants266 Participants210 Participants153 Participants489 Participants5488 Participants
Race/Ethnicity, Customized
Asian
9569 Participants724 Participants347 Participants249 Participants1114 Participants12003 Participants
Race/Ethnicity, Customized
Black
4121 Participants127 Participants91 Participants22 Participants403 Participants4764 Participants
Race/Ethnicity, Customized
Missing
48059 Participants3054 Participants2167 Participants1229 Participants4501 Participants59010 Participants
Race/Ethnicity, Customized
Mixed
1483 Participants85 Participants67 Participants44 Participants150 Participants1829 Participants
Race/Ethnicity, Customized
Other
1448 Participants93 Participants54 Participants26 Participants123 Participants1744 Participants
Race/Ethnicity, Customized
White
148832 Participants10099 Participants6763 Participants4727 Participants17119 Participants187540 Participants
Sex: Female, Male
Female
128129 Participants7056 Participants5193 Participants3204 Participants16634 Participants160216 Participants
Sex: Female, Male
Male
85383 Participants7126 Participants4296 Participants3093 Participants6776 Participants106674 Participants
Smoking status
Current Smoker
52035 Participants2574 Participants2914 Participants1519 Participants6063 Participants65105 Participants
Smoking status
Ex-Smoker
63798 Participants5147 Participants2551 Participants2232 Participants8385 Participants82113 Participants
Smoking status
Non-Smoker
94985 Participants6328 Participants3917 Participants2522 Participants8853 Participants116605 Participants
Smoking status
Smoking status not recorded
2694 Participants133 Participants107 Participants24 Participants109 Participants3067 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
deaths
Total, all-cause mortality
0 / 00 / 00 / 00 / 00 / 0
other
Total, other adverse events
0 / 00 / 00 / 00 / 00 / 0
serious
Total, serious adverse events
0 / 00 / 00 / 00 / 00 / 0

Outcome results

Primary

Risk of Venous Thromboembolism (VTE)

Number of participants with systemic inflammatory disorders developing VTE (a composite of pulmonary embolism (PE) and deep vein thrombosis (DVT)) compared to population controls.

Time frame: A 20 year analysis period (1999-2018 inclusive)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
People With Ulcerative Colitis (UC)Risk of Venous Thromboembolism (VTE)335 Participants
People With Rheumatoid ArthritisRisk of Venous Thromboembolism (VTE)845 Participants
People With Psoriatic ArthritisRisk of Venous Thromboembolism (VTE)132 Participants
ControlsRisk of Venous Thromboembolism (VTE)3804 Participants
People With Crohn's DiseaseRisk of Venous Thromboembolism (VTE)220 Participants
Secondary

Risk of Deep Vein Thrombosis (DVT)

Number of participants with systemic inflammatory disorders developing DVT compared to population controls.

Time frame: A 20 year analysis period (1999-2018 inclusive)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
People With Ulcerative Colitis (UC)Risk of Deep Vein Thrombosis (DVT)207 Participants
People With Rheumatoid ArthritisRisk of Deep Vein Thrombosis (DVT)542 Participants
People With Psoriatic ArthritisRisk of Deep Vein Thrombosis (DVT)89 Participants
ControlsRisk of Deep Vein Thrombosis (DVT)2335 Participants
People With Crohn's DiseaseRisk of Deep Vein Thrombosis (DVT)140 Participants
Secondary

Risk of Pulmonary Embolism (PE)

Number of participants with systemic inflammatory disorders developing PE compared to population controls.

Time frame: A 20 year analysis period (1999-2018 inclusive)

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
People With Ulcerative Colitis (UC)Risk of Pulmonary Embolism (PE)149 Participants
People With Rheumatoid ArthritisRisk of Pulmonary Embolism (PE)373 Participants
People With Psoriatic ArthritisRisk of Pulmonary Embolism (PE)52 Participants
ControlsRisk of Pulmonary Embolism (PE)1737 Participants
People With Crohn's DiseaseRisk of Pulmonary Embolism (PE)98 Participants

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026